Business NewsPR NewsWire • BerGenBio ASA: Results for the First Quarter 2020

BerGenBio ASA: Results for the First Quarter 2020

BerGenBio ASA: Results for the First Quarter 2020

BERGEN, Norway, May 19, 2020 /PRNewswire/ -- BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for unmet medical need, announces its results for the first quarter 2020. A live webcast presentation by the Company's...

View More : https://www.prnewswire.com:443/news-releases/bergenbio-asa-results-for-the-first-quarter-2020-301061397.html
Releted News by prnewswire
Medela ouvre une nouvelle ligne de production aux États-Unis et multiplie par plus de trois la production en Suisse de systèmes d'aspiration portatifs essentiels pour contribuer à l'assistance ventilatoire en hôpital et aider les patients touchés par le COVID-19
Samsung Biologics Expands Business Continuity Excellence with Additional ISO 22301 Certification
BerGenBio ASA: Results for the First Quarter 2020
Společnost Huobi a nevládní organizace uznaná OSN společně zahajují charitativní kampaň COVID-19
Magnesium Alloys Market Size Worth $6.6 Billion by 2027 | CAGR: 9.9%: Grand View Research, Inc.